Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report.
Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colorectal cancer. Necrotising fasciitis is a rare complication affecting one in 5000 bevacizumab users. We report the case of a 64-year-old man with stage IV rectosigmoid cancer under treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) and aflibercept, who developed a Fournier's gangrene.
['Gonzaga-López|A|A|', 'Muñoz-Rodriguez|J|J|', 'Ruiz-Casado|A|A|']
D000970:Antineoplastic Agents D000971:Antineoplastic Combined Chemotherapy Protocols D000068258:Bevacizumab D002166:Camptothecin D015179:Colorectal Neoplasms D019115:Fasciitis, Necrotizing D017809:Fatal Outcome D005472:Fluorouracil D018934:Fournier Gangrene D006801:Humans D002955:Leucovorin D008297:Male D008875:Middle Aged D040262:Receptors, Vascular Endothelial Growth Factor D011993:Recombinant Fusion Proteins
Necrotising fasciitis Bevacizumab Aflibercept Angiogenesis inhibitor Colorectal neoplasms